Reunion Neuroscience
Toronto
About Reunion Neuroscience
Reunion Neuroscience is a clinical-stage pharmaceutical company developing therapeutic solutions for underserved mental health conditions. The Company’s lead asset, RE104, is a proprietary, novel serotonergic psychedelic compound being developed as a potential fast-acting and durable antidepressant for patients suffering from postpartum depression and other mental health conditions. Reunion is also developing the RE200 series, which includes compounds with the potential for more selective serotonin receptor activity and reduced psychoactivity for application in more chronic treatment paradigms and indications.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $133.0M
- Funding stage: M&A
- Last round: Series A (Sep 2025)
- Ticker: nasdaq:REUN
- Website: reunionneuro.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Mental Health, Neuroscience, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/reunion-neuroscience-93684 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.